Noninvasive Prenatal
Screening (NIPS)

Get accurate prenatal insights as early as week 10 with Verifi

NIPS is a blood-based genetic, prenatal screening test of the pregnant person that screens for common chromosomal conditions that affect a baby’s health.

This test, performed on the Illumina VeriSeq NIPS Solution v2 platform, uses counting-based analysis to determine the probability that certain regions of the genome are over- or underrepresented. Data are generated through massively parallel whole genome sequencing. This process analyzes cell-free DNA (cfDNA) to generate paired-end data that are then compared with a reference genome. The comparisons help detect the likelihood of chromosomal abnormalities in the fetus. Results are reported as aneuploidies detected or not detected.

NIPS delivers more accurate than maternal serum screening methods for detecting fetal chromosome aneuploidies and is used for screening in women carrying a single fetus or twins and can be performed as early as 10 weeks into a pregnancy. It requires a maternal blood draw and carries no risk of miscarriage. The high-efficiency screening process is also fast and can deliver results to patients within five to seven days.

Verifi™ is a screening test, which means that this test does not make a final diagnosis. A positive result means that your pregnancy has a higher chance of having a specific genetic condition. However, you cannot know for sure if your baby has that condition based upon the screening result alone. All medical decisions should be made after discussion with your care team regarding diagnostic testing during the pregnancy, like chorionic villus sampling (CVS) or amniocentesis, or testing the baby after birth.

Insights into genetic health risks


  • Provides accurate prenatal insights as early as week 10
  • Is as safe and simple as a blood draw
  • Gives insights into genetic health risks with greater than 99% accuracy
  • Broadest screening window of any prenatal aneuploidy screening test
  • Is available for all pregnant women
  • Reduces the number of invasive confirmatory procedures performed in unaffected pregnancies
  • Has a high reported detection rate for Down syndrome
  • Has low reported false positive rate for Down syndrome

Compared to conventional prenatal serum screening, Verifi™ has:

  • Lower false-positive rates
  • Higher detection rates of Down Syndrome (T21), Edwards Syndrome (T18), and Patau Syndrome (T13)

>99% accuracy for trisomies 21, 18, and 13


Gain insights into prenatal genetic health risks as early as week 10


Reduce the number of invasive procedures in unaffected pregnancies




screens for common genetic conditions that are caused by extra or missing chromosomes in the baby’s DNA and rare autosomal conditions caused by gene mutations. Some conditions, such as Down syndrome, are caused by extra copies of a specific chromosome. Others, such as microdeletions, occur when a chromosome is missing a small piece of genetic information. Verifi™ screens for:

  • Common aneuploidies (trisomies 21, 18, and 13)
  • Rare autosomal aneuploidies
  • Sex chromosome aneuploidies
  • Copy number variants